Background: Observational studies have suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback